BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Testicular cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
16 results:

  • 1. Genomic landscape and distinct molecular subtypes of primary testicular lymphoma.
    Zhang W; Yang P; Yang Y; Liu S; Xu Y; Wu C; Wang J; Liu C; Liu H; Li S; Huang W; Jing H
    J Transl Med; 2024 May; 22(1):414. PubMed ID: 38693538
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
    Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
    Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Diagnosis and treatment of malignant mesothelioma of the tunica vaginalis testis: a series of 7 cases].
    Huang KB; Cao Y; Yao K; Zhou FJ; Liu ZW; Li XD
    Zhonghua Wai Ke Za Zhi; 2023 Sep; 61(9):812-817. PubMed ID: 37491176
    [No Abstract]    [Full Text] [Related]  

  • 4. Primary testicular lymphoma demonstrates overexpression of the Wilms tumor 1 gene and different mRNA and miRNA expression profiles compared to nodal diffuse large B-cell lymphoma.
    Mansoor A; Akhter A; Shabani-Rad MT; Deschenes J; Yilmaz A; Trpkov K; Stewart D
    Hematol Oncol; 2023 Dec; 41(5):828-837. PubMed ID: 37291944
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. TIMEAS, a promising method for the stratification of testicular germ cell tumor patients with distinct immune microenvironment, clinical outcome and sensitivity to frontline therapies.
    Meng J; Gao J; Li X; Gao R; Lu X; Zhou J; Yan F; Wang H; Liu Y; Hao Z; Zhang X; Liang C
    Cell Oncol (Dordr); 2023 Jun; 46(3):745-759. PubMed ID: 36823338
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Analysis of gene expression levels and their impact on survival in 31 cancer-types patients identifies novel prognostic markers and suggests unexplored immunotherapy treatment options in a wide range of malignancies.
    Giampietri C; Scatozza F; Crecca E; Vigiano Benedetti V; Natali PG; Facchiano A
    J Transl Med; 2022 Oct; 20(1):467. PubMed ID: 36224560
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Metachronous testicular Metastases from Merkel Cell Carcinoma (MCC): A Case Report and Literature Review.
    Laffi A; Cozzi G; Spada F; Fazio N; Bertuzzi AF; Santoro A
    Am J Case Rep; 2022 Aug; 23():e936552. PubMed ID: 36031755
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Sperm Autoantigenic Protein 17 Predicts the prognosis and the Immunotherapy Response of cancers: A Pan-cancer Analysis.
    Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
    Front Immunol; 2022; 13():844736. PubMed ID: 35592314
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Immune mechanisms and possible immune therapy in testicular germ cell tumours.
    Chovanec M; Mardiak J; Mego M
    Andrology; 2019 Jul; 7(4):479-486. PubMed ID: 31169364
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Phase II study of avelumab in multiple relapsed/refractory germ cell cancer.
    Mego M; Svetlovska D; Chovanec M; Rečkova M; Rejlekova K; Obertova J; Palacka P; Sycova-Mila Z; De Giorgi U; Mardiak J
    Invest New Drugs; 2019 Aug; 37(4):748-754. PubMed ID: 31152292
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer.
    Oing C; Bokemeyer C
    Curr Opin Urol; 2018 Sep; 28(5):479-484. PubMed ID: 29957683
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
    Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
    J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Systemic immune-inflammation index in germ-cell tumours.
    Chovanec M; Cierna Z; Miskovska V; Machalekova K; Kalavska K; Rejlekova K; Svetlovska D; Macak D; Spanik S; Kajo K; Babal P; De Giorgi U; Mego M; Mardiak J
    Br J Cancer; 2018 Mar; 118(6):831-838. PubMed ID: 29485980
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Prognostic role of programmed-death ligand 1 (pd-l1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
    Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
    Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
    Nayak L; Iwamoto FM; LaCasce A; Mukundan S; Roemer MGM; Chapuy B; Armand P; Rodig SJ; Shipp MA
    Blood; 2017 Jun; 129(23):3071-3073. PubMed ID: 28356247
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (pd-l1) in testicular germ cell tumors.
    Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
    Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.